Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
F 10.29 -3.11% -0.33
BYSI closed down 3.11 percent on Friday, April 9, 2021, on 55 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BYSI trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -3.11%
Oversold Stochastic Weakness -3.11%
Oversold Stochastic Weakness 0.19%
Oversold Stochastic Weakness -3.74%
Oversold Stochastic Weakness -3.20%
180 Bearish Setup Bearish Swing Setup -4.72%
Oversold Stochastic Weakness -4.72%
Older End-of-Day Signals for BYSI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 18 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Down 2 % about 19 hours ago
Rose Above Previous Day's High about 21 hours ago
10 DMA Resistance about 21 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


BeyondSpring, Inc. Description

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatments Chemotherapy Small Cell Lung Cancer Antineoplastic Drugs Organic Chemistry Cancer Therapies Nsclc Protein Kinase Docetaxel Advanced Non Small Cell Lung Cancer Neutropenia Buparlisib Imidazoles

Is BYSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 21.5
52 Week Low 9.83
Average Volume 250,796
200-Day Moving Average 13.02
50-Day Moving Average 12.67
20-Day Moving Average 11.43
10-Day Moving Average 10.67
Average True Range 0.68
ADX 24.38
+DI 15.52
-DI 25.17
Chandelier Exit (Long, 3 ATRs ) 11.09
Chandelier Exit (Short, 3 ATRs ) 12.15
Upper Bollinger Band 13.19
Lower Bollinger Band 9.67
Percent B (%b) 0.18
BandWidth 30.80
MACD Line -0.64
MACD Signal Line -0.59
MACD Histogram -0.0509
Fundamentals Value
Market Cap 402.77 Million
Num Shares 39.1 Million
EPS -1.90
Price-to-Earnings (P/E) Ratio -5.42
Price-to-Sales 0.00
Price-to-Book 18.22
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.19
Resistance 3 (R3) 11.24 11.00 11.04
Resistance 2 (R2) 11.00 10.77 10.97 10.99
Resistance 1 (R1) 10.64 10.63 10.52 10.59 10.94
Pivot Point 10.40 10.40 10.34 10.37 10.40
Support 1 (S1) 10.04 10.17 9.92 9.99 9.64
Support 2 (S2) 9.80 10.03 9.77 9.59
Support 3 (S3) 9.44 9.80 9.54
Support 4 (S4) 9.39